FUMAGALLI, CATERINA
FUMAGALLI, CATERINA
Universita' degli Studi di MILANO
A novel algorithm to implement the molecular classification according to the new ESGO/ESTRO/ESP 2020 guidelines for endometrial cancer
2022 I. Betella, C. Fumagalli, P. Rafaniello Raviele, G. Schivardi, L.A. De Vitis, M.T. Achilarre, A. Aloisi, A. Garbi, M. Maruccio, V. Zanagnolo, G. Aletti, E. Guerini-Rocco, A. Mariani, A. Maggioni, M. Barberis, N. Colombo, F. Multinu
CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer
2016 S. Rizzo, F. Petrella, V. Buscarino, F. de Maria, S. Raimondi, M. Barberis, C. Fumagalli, G. Spitaleri, C. Rampinelli, F. de Marinis, L. Spaggiari, M. Bellomi
Phase Ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets
2014 F. Toffalorio, G. Spitaleri, C. Catania, L. Dal Zotto, C. Noberasco, A. Delmonte, M. Santarpia, F. Vecchio, V. Brunelli, C. Rampinelli, M. Barberis, C. Fumagalli, M. Zucchetti, M. Zangarini, T. Diena, R. Danesi, F. De Braud, T. De Pas
Gene expression profiling reveals GC and CEACAM1 as new tools in the diagnosis of lung carcinoids
2014 F. Toffalorio, E. Belloni, M. Barberis, G. Bucci, L. Tizzoni, G. Pruneri, C. Fumagalli, G. Spitaleri, C. Catania, F. Melotti, P.G. Pelicci, L. Spaggiari, T. De Pas
Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations
2011 T. De Pas, F. Toffalorio, M. Manzotti, C. Fumagalli, G. Spitaleri, C. Catania, A. Delmonte, M. Giovannini, L. Spaggiari, F. de Braud, M. Barberis